Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05311592 · ClinicalTrials.gov registry record · NA
Supporting Responsible Fatherhood Program (Fatherhood FIRE)
A NA study, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 496
- Enrollment target
NCT05311592: Completed NA study, sponsored by Montefiore Medical Center.
NCT05311592 is a NA study that has completed, run by Montefiore Medical Center. The registered enrollment target is 496 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05311592, a NA study, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 496 participants
- Enrollment target
Study Summary
Montefiore Medical Center (in partnership with BronxWorks) is implementing a large-scope program to promote responsible fatherhood in the Bronx among low-income adult (18 years or older) fathers with non-custodial children (under the age of 24). The program, called HERO Dads (Healthy, Empowered, Resilient, Open Dads), will promote responsible fatherhood by enhancing relationship and anger-management skills and providing marriage education; providing skills-based parenting education, disseminating information about good parenting practices, and encouraging child support payments (in partnership with our local OCSE); and fostering economic stability by providing employment-related supports inclusive of job search, vocational skills training, job referrals, and job retention.
Primary Outcome
Fatherhood Involvement will be assessed using the Inventory of Fatherhood Involvement short form (IFI) questionnaire. The IFI is a 26-item self-report instrument that assesses indirect and direct father involvement using a 7- point Likert scale ranging from 0 (very poor) to 6 (excellent). This measure addresses the 3 main domains of father involvement: engagement, accessibility, and responsibility. Overall scores can therefore range from 0 to 156. Higher scores represent increased levels of enga
Interventions
- BEHAVIORAL HERO Dads Program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 496 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2025-06-10 |
| Phase | NA |
What the finished NCT05311592 record still lists
NCT05311592 is an interventional study that assigns participants to a tested intervention. The registered 496 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 1 intervention - of which HERO Dads Program is the first listed.
NCT05311592 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05311592 about?
NCT05311592 is a clinical study titled "Supporting Responsible Fatherhood Program (Fatherhood FIRE)". Montefiore Medical Center (in partnership with BronxWorks) is implementing a large-scope program to promote responsible fatherhood in the Bronx among low-income adult (18 years or older) fathers with non-custodial children (under the age of 24). The program, called HERO Dads (Healthy, Empowered, Res...
What is the current status of trial NCT05311592?
This trial is currently completed. It is a NA study. The enrollment target is 496 participants. The study started on 2021-04-01. Estimated completion is 2025-06-10.
What interventions are being tested in trial NCT05311592?
The interventions under investigation include: HERO Dads Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT05311592?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05311592's enrollment target sits among peer trials
496 213th of 2000 higher than 1,788 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283720 · 496 participants · Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- NCT06417775 · 496 participants · Phase 3
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
- NCT06778447 · 496 participants · NA
Clinical Trial Evaluating the Safety and Efficacy of Nucleus Pulposus Allograft in Participants With Degenerative Disc Disease
- NCT03175224 · 497 participants · Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI